XenoHelix announced that it successfully participated in Cosmetic Inside Korea 2025, held from April 22 to 25, 2025, at KINTEX in Ilsan. During the exhibition, the company highlighted its premium exosome and Micro-PDRN (Polydeoxyribonucleotide) materials, both engineered using its proprietary microRNA precision diagnostic technology.

 

XenoHelix possesses specialized core technologies for targeting microRNA, which is traditionally difficult to isolate and detect. Utilizing this platform, the company is actively developing diagnostics for Parkinson's disease and liver conditions—milestones that have earned prestigious national R&D grants valued at KRW 4.6 billion and KRW 6 billion, respectively.

 

By cross-applying this advanced microRNA expertise to the development of revolutionary skin booster ingredients, XenoHelix has successfully engineered Micro-PDRN. Composed of a 20-base-pair sequence designed to match the precise scale of microRNA, Micro-PDRN is tens to hundreds of times smaller than conventional PDRN. XenoHelix explained that this ultra-small molecular structure guarantees exceptionally high skin permeability and delivers immediate, targeted efficacy.

Furthermore, XenoHelix has developed a proprietary manufacturing process that directly extracts exosomes—with microRNA as the primary active component—from premium botanical sources such as Red Ginseng and Centella Asiatica (Byeongpul). Cultivated under optimal photosynthetic environments, these phytochemically enhanced exosome materials are already being commercialized and shipped to key markets including the Middle East, Canada, and South Korea.

 

"The superior efficacy of our developed Micro-PDRN and plant-derived exosomes has already been robustly validated through extensive performance testing," a XenoHelix representative stated. "We have clinically and scientifically proven their performance by rigorous analysis of the exact molecular size of our Micro-PDRN and the precise microRNA profiling within our exosome structures."